p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status

Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End

(2016) Amanda R. Wasylishen et al.   Cold Spring Harbor Perspectives in Medicine

Progeny Clustering: A Method to Identify Biological Phenotypes

(2015) Chenyue W. Hu et al.   Scientific Reports

RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis

(2014) P. S. Winter et al.   Science Signaling

Systematic identification of signaling pathways with potential to confer anticancer drug resistance

(2014) C. A. Martz et al.   Science Signaling

A pan-cancer proteomic perspective on The Cancer Genome Atlas

(2014) Rehan Akbani et al.   Nature Communications

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal

(2010) Z. Zhao et al.   GENES & DEVELOPMENT

Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial

(2010) F Stölzel et al.   LEUKEMIA

Variable slope normalization of reverse phase protein arrays

(2009) E. Shannon Neeley et al.   BIOINFORMATICS

The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia

(2009) H Seifert et al.   LEUKEMIA

Trim24 targets endogenous p53 for degradation

(2009) Kendra Allton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Functional proteomic profiling of AML predicts response and survival

(2008) S. M. Kornblau et al.   BLOOD

Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia

(2008) Hareth Nahi et al.   LEUKEMIA & LYMPHOMA